ocal injections versus eyedrops Interferon in ocular surface squamous neoplasia
Phase 4
- Conditions
- Health Condition 1: C690- Malignant neoplasm of conjunctiva
- Registration Number
- CTRI/2024/03/064353
- Lead Sponsor
- Dr Rajendra Prasad Centre of Ophthalmic Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
All clinically and cytologically diagnosed OSSN
Patient willing to participate and follow up
Exclusion Criteria
Patient already on topical or perilesional immunotherapy/chemotherapy
/radiotherapy
Patient having any comorbidity
Intraocular or orbital OSSN (AJCC stage T3 OR T4)
Study & Design
- Study Type
- PMS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Outcome of treatment response clinically (Measured using slit lamp photography) <br/ ><br> <br/ ><br>Severity of side effects(flu like syndrome, hyperemia/follicular conjunctivitis) by each treatment modality <br/ ><br> <br/ ><br>Duration of recurrences if anyTimepoint: 1 month,2 month,3 month,4 month
- Secondary Outcome Measures
Name Time Method To analyse changes in ocular surface using (OSA) ocular surface analyser (Tear osmolarity/ Lipid layer thickness/Tear meniscus/Non invasive breakup time/ Meibography/Ocular redness classification)Timepoint: 1 month,2 month,3 month,4 month